Biocon's branded business gets a boost with anti-cancer drug

 

Biocon plans to increase the share of branded formulations in its sales to 20 per cent, from 14 per cent at present, as it targets $1 billion revenue by end of FY 2019. 

At present, Biocon sells branded formulations, including biologics and biosimilars, in India and the UAE. The company plans to expand the business with the launch of new products and entry into new markets. In 2016-17, Biocon reported revenue of Rs 4,078 crore.

The company on Thursday launched the anti-cancer biosimilar Bevicazumab under the brand name Krabeva. Biocon said the drug featured a unique mechanism that would